Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients

Neuroendocrinology Letters

Volumn 29, Issue 6, 2008, Pages 971-976

  Vališ, Martin ^a   Taláb, Radomír ^a   Šťourač, Pavel ^b   Andrýs, Ctirad ^a   Masopust, Jiri ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Beta amyloid42; Cerebrospinal fluid; Clinically isolated syndrome; Multiple sclerosis; Phosphorylated tau protein; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; IMMUNOASSAY; MULTIPLE SCLEROSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

EID: 59849092370     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K (2001). Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem. 267: 37967-73.
2. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B et al (1999). Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 56: 673-683.
3. Baranowska-Bik A, Bik W, Wolinska-Witort E, Martynska L, Chmielowska M, Barcikowska M et al (2008). Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuroendocrinol Lett. 29: 75-79.
4. Bartosik-Psujek H, Archelos JJ (2004). Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol. 251: 414-420.
5. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J, et al (2005). Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler. 11: 261-265.
6. Brettschneider J, Petzhold A, Junker A, Tumani H (2006). Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler. 12: 143-148.
7. Buée L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 33: 95-130.
8. Drewes G (2004). Marking tau for tangles and toxicity. Trends Biochem Sci. 29: 548-555.
9. Dumont D, Noben JP, Raus J, Stinissen P, Robben J (2004). Proteomic analysis of cerebrospinal fluid from multiple sclerosis. Proteomics. 4: 2117-2124.
10. Farkas I, Czigner A, Farkas E, Dobó E, Soós K et al (2003). Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain. Acta Histochemica. 105: 115-125.
11. Guimarães I, Cardoso MI, Sa MJ (2006). Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler. 12: 354-356.
12. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P et al (2000).Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimer Dis. 2: 199-206.
13. Holmberg B, Johnels B, Blennow K, Rosengren L (2003). Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 18: 186-190.
14. Hort J, Vališ M, Waberzinek G, Taláb R, Grossová L, Bojar M et al (2008). Bedeutung der gesamt-τ- und phospho-τ-protein-liquor-spiegel in der demenzdiagnostik. [(Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia.) (In German)] Nervenarzt.
15. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al (1999). Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 52: 155-162.
16. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994). Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron. 13: 45-53.
17. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N et al (1999). Cerebrospinal fluid A β42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neural. 45: 504-511.
18. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001). Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD:a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 71: 401-403.
19. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K (2000). CSF tau is increased in multiple sclerosis. Eur Neurol. 43: 228-232.
20. Kapaki E, Paraskevas GP, Zalonis I, Zournas C (2003). CSF tau protein and β-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol. 10: 119-128.
21. Ledesma M.,Medina M, Avila J (1996). The in-vitro formation of recombinant tau polymer effect of phosphorylation and glycation. Mol Chem Neuropathol. 27: 249-258.
22. Luque FA, Jaffe SL (2007). Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol. 79: 341-356.
23. Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998). Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 64: 402-404.
24. McDonald WI, Compston A, Fdan G, Goodkin D, Hartung HP, Lublin FD et al (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 50: 121-127.
25. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000). Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57: 100-105.
26. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993). Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 301: 41-52.
27. Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CL, Fu PC et al (1995). Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 25: 207-217.
28. Nagga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Dissord. 14: 183-190.
29. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J et al (1997). Elevated levels of tau protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 225: 210-212.
30. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P et al (2000). Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 54: 1099-1102
31. Perry VH, Anthony DC, Bolton SJ, Brown HC (1997). The blood-brain barrier and the inflammatory response. Mol Med Today. 8: 335-341.
32. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al (2005). Diagnostic criteria far multiple sclerosis: 2005 revisions to the" McDonald Criteria". Ann Neural. 58: 840-846.
33. Raedler TJ, Wiedemann K (2006). CSF-studies in neuropsychiatric disorders. Neuroendocrinol Lett. 27: 297-305.
34. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995). Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45: 51-55.
35. Sjögren M, Davidsson P, Wallin A, Granerus AK, Grundström E, Askmark H et al (2002). Decreased CSF β-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dement Geriatr Cogn Disord. 13: 112-118.
36. Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, Vanderstichele H et al (2000). CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 107: 563-579
37. Small DH, McLean CA (1999). Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J Neurochem. 73: 443-449.
38. Strozyk D, Blennow K, White LR, Launer LJ (2003). CSF Aβ42 levels correlate with amyboid-neuropathology in a population-based autopsy study. Neurology. 60: 652-656.
39. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al (2003). Decreased β-amyboid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 289: 2094-2103
40. Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K et al (1994). Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun. 205: 834-842.
41. Trapp BD, Peterson J, Ransohoff RM, Rudic R, Mörk S, Bö L (1998). Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338: 278-285.
42. Trojanowski JQ, Lee VM (2002). The role of tau in Alzheimer's disease. Med Clin North Am. 86: 615-627.
43. Vališ M, Taláb R, Andrýs C, Štourǎ P, Masopust J, Kalnická D et al (2008). Tau protein, fosforylovaný tau protein a beta-amyloid42 v likvoru u demencí a roztroušené sklerózy. Cesk Slov Neurol N. 71/104: 329-335.
44. Van Everbroeck B, Green A, Vanmechelen F, Vanderstichele H, Pals P, Sanchez-Valle R et al (2002). Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 73: 79-81.
45. Vanderstichele H, Blennow K, D'Heuvaert ND, Buyse MA, Wallin A, Andreasen N et al. (1998). Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, editors. Progress in Alzheimers and Parkinson's diseases. New York: Plenum. p. 773-778.
46. Weingarten MD, Lockwood AH, Hwo SY, Kirchner MW (1975). A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 72: 1858-1862.
47. Zlokovic BV (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57: 178-201.